February 8th, 2017 - Nanosyn announced today a continuation of an initiative seeking new therapeutic avenues for several incurable human diseases, including high grade pediatric brain tumors, primary liver cholangiocarcinomas, and amyotrophic lateral sclerosis.
The core collaboration in the Epigenetic Research Initiative with the Mayo Clinic Center for Clinical and Translational Science Office of Translation to Practice (OTP) includes two critical components: the cell-based disease models previously validated by Mayo Clinic researchers, with support from the Mayo Clinic Center for Individualized Medicine and the Pathway Identification technological platform supplied by Nanosyn.
The research initiative is managed by the OTP, in concert with the office’s mission to accelerate the development and uptake of new products which help patients in clinical practice, and involves several multidisciplinary teams. Each team includes Mayo principal investigators working alongside Nanosyn scientists with extensive industry experience in drug discovery and development.
“We are very delighted to team up with the Mayo and envision this collaboration as a unique opportunity to utilize our technology in the real clinical research environment,” says Olga Issakova, Executive Vice President of Nanosyn.
Nanosyn (www.nanosyn.com) is a Contract Research Organization providing integrated drug discovery and development services, medicinal chemistry, made-to-order focused compound libraries, lead optimization, assay development, screening and profiling services, process chemistry, and other innovative solutions to meet our partners' drug discovery needs. Founded in 1998, Nanosyn is a privately held and self-sustaining team of expert scientists. The company is headquartered in the San Francisco Bay Area, California with discovery site in Santa Clara, CA and cGMP kilo lab in Santa Rosa, CA. For inquiries and additional information, contact Olga Issakova, Ph.D., Executive Vice President, at 650-269-3528.